Penumbra (PEN) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
1.2B
Gross Profit
755.0M
63.20%
Operating Income
86.2M
7.22%
Net Income
14.0M
1.17%
EPS (Diluted)
$0.36
Balance Sheet Metrics
Total Assets
1.5B
Total Liabilities
382.2M
Shareholders Equity
1.2B
Debt to Equity
0.33
Cash Flow Metrics
Operating Cash Flow
36.8M
Free Cash Flow
147.3M
Revenue & Profitability Trend
Penumbra Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 1.2B | 1.1B | 847.1M | 747.6M | 560.4M |
| Cost of Goods Sold | 439.6M | 375.9M | 311.9M | 272.2M | 222.2M |
| Gross Profit | 755.0M | 682.6M | 535.2M | 475.4M | 338.2M |
| Operating Expenses | 668.8M | 590.9M | 529.1M | 482.9M | 377.1M |
| Operating Income | 86.2M | 91.8M | 6.1M | -7.5M | -38.9M |
| Pre-tax Income | 20.9M | 79.6M | 3.9M | -10.5M | -38.0M |
| Income Tax | 6.9M | -11.3M | 5.9M | -13.1M | -18.8M |
| Net Income | 14.0M | 91.0M | -2.0M | 2.6M | -19.3M |
| EPS (Diluted) | $0.36 | $2.32 | -$0.05 | $0.14 | -$0.44 |
Income Statement Trend
Penumbra Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 951.1M | 915.4M | 755.7M | 681.5M | 617.7M |
| Non-Current Assets | 582.1M | 640.9M | 615.2M | 562.8M | 205.3M |
| Total Assets | 1.5B | 1.6B | 1.4B | 1.2B | 823.0M |
| Liabilities | |||||
| Current Liabilities | 158.3M | 151.1M | 144.9M | 123.2M | 105.9M |
| Non-Current Liabilities | 223.9M | 226.2M | 227.1M | 167.1M | 79.3M |
| Total Liabilities | 382.2M | 377.4M | 372.0M | 290.3M | 185.2M |
| Equity | |||||
| Total Shareholders Equity | 1.2B | 1.2B | 998.9M | 953.9M | 637.8M |
Balance Sheet Composition
Penumbra Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 14.0M | 91.0M | -2.0M | 2.6M | -19.3M |
| Operating Cash Flow | 36.8M | 103.8M | -68.4M | 2.6M | -60.7M |
| Investing Activities | |||||
| Capital Expenditures | -21.2M | -15.2M | -19.3M | -21.2M | -24.8M |
| Investing Cash Flow | 77.6M | -16.1M | 54.8M | -21.7M | -104.1M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | -104.2M | -4.2M | -9.9M | -17.5M | 118.4M |
| Free Cash Flow | 147.3M | 82.1M | -75.0M | -11.7M | -58.0M |
Cash Flow Trend
Penumbra Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
235.61
Forward P/E
67.32
Price to Book
8.12
Price to Sales
7.95
PEG Ratio
67.32
Profitability Ratios
Profit Margin
3.41%
Operating Margin
12.45%
Return on Equity
3.50%
Return on Assets
5.82%
Financial Health
Current Ratio
6.30
Debt to Equity
18.19
Beta
0.49
Per Share Data
EPS (TTM)
$1.08
Book Value per Share
$31.35
Revenue per Share
$32.13
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| pen | 9.9B | 235.61 | 8.12 | 3.50% | 3.41% | 18.19 |
| Abbott Laboratories | 231.9B | 17.31 | 4.75 | 30.65% | 31.89% | 27.09 |
| Boston Scientific | 149.9B | 73.94 | 6.75 | 9.50% | 11.58% | 52.16 |
| Stryker | 148.0B | 52.39 | 7.07 | 14.26% | 12.31% | 82.92 |
| Medtronic plc | 110.3B | 23.84 | 2.30 | 9.51% | 13.90% | 61.39 |
| Edwards Lifesciences | 43.3B | 30.51 | 4.27 | 16.51% | 75.71% | 6.86 |
Financial data is updated regularly. All figures are in the company's reporting currency.